Valeant Pulls Appeal Of Patent Suit Vs. Three Rivers, Par Pharma

Law360, New York (June 7, 2004, 12:00 AM EDT) -- Drug maker Valeant has withdrawn an appeal to a patent infringement lawsuit that had been scheduled for oral arguments before the U.S. Court of Appeals for the Federal Circuit this week.

In July 2003, drug maker Three Rivers and marketing partner Par Pharmaceutical obtained summary judgment of non-infringement in the U.S. District Court for the Central District of California.

Valeant had sued the two drug makers over their plans to launch a treatment for Hepatitis C. They launched their drug, Ribasphere (Ribavirin capsules) 200 mg, in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.